Osborne Clarke advised London listed Oxford Biomedica plc on the French law aspects of its acquisition of 100% of the shares of ABL Europe SAS from Institut Mérieux.

Oxford Biomedica is a world-leading cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in the UK, the EU and the US.

ABL Europe is a European CDMO specialised in viral vector development and manufacturing, with facilities in Lyon and Strasbourg. Focused on delivering GMP-compliant viral vectors from early-stage to market, ABL Europe plays a pivotal role in the success of client-focused gene and immunotherapy solutions.

The Osborne Clarke teams for Oxford Biomedica:

Lead – M&ACatherine Olive, partner – Julie Dahan, senior associate – Anthony Chung, associate.

Employment Law Jérôme Scapoli, partner – Maud Parssegny and Alexandra Mestrallet, associates.

Commercial, Life SciencesThomas Devred, partner – Justine Pellerin, associate.

IP/ IT/ Data: Xavier Pican, partner – Alice Vigne, associate.

Real estate: François-Régis Fabre-Falret, partner – Julia Gaspard, counsel.

TaxDorothée Chambon, partner – Clément Petit, senior associate – Aminata Sarre, associate.

Compliance lawLucie Mongin-Archambeaud, partner – Lucie Champetier, associate.

Client relationship: Matthew Edwards, partner UK.

Corporate communications and press contacts

If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.